RIASTAP®

FDA INDICATION: For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Package Insert

CLASS: Human

DISTRIBUTOR: CSL Behring

ROUTE OF ADMINISTRATION: Intravenous

ASSAY SIZES (mg): 900–1300

DILUENT SIZE: 50 mL

STORAGE: When stored at temperatures of 2–25°C (36–77°F), RiaSTAP is stable for the period indicated by the expiration date on the carton and vial label (up to 60 months). Do not freeze. Protect from light

HALF-LIFE: 78.7 ± 18.13 hours

OTHER WEBSITES: riastap.com